Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.
(2015) In International Journal of Endocrinology 2015.- Abstract
- The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard... (More)
- The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard deviation, CONGA, J-INDEX, and MAGE. We found that vildagliptin improved the glycemic condition compared to placebo: mean glycemic levels, and both GRADE and M-VALUE, were reduced by vildagliptin (P < 0.01). Indices also showed that vildagliptin reduced glycemia without increasing the risk for hypoglycemia. Almost all indices of glycemic variability showed an improvement of the glycemic condition with vildagliptin (P < 0.02), though more marked differences were shown by the more complex indices. In conclusion, the study shows that four-sample preprandial glucose self-monitoring is sufficient to yield information on the vildagliptin effects on glycemic control and variability. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8235066
- author
- Tura, Andrea ; Farngren, Johan LU ; Schweizer, Anja ; Foley, James E ; Pacini, Giovanni and Ahrén, Bo LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Endocrinology
- volume
- 2015
- article number
- 484231
- publisher
- Hindawi Limited
- external identifiers
-
- pmid:26587020
- wos:000364705700001
- scopus:84947598664
- pmid:26587020
- ISSN
- 1687-8337
- DOI
- 10.1155/2015/484231
- language
- English
- LU publication?
- yes
- id
- 6b7bd893-dece-465e-8e35-f82be786355e (old id 8235066)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26587020?dopt=Abstract
- date added to LUP
- 2016-04-01 11:14:54
- date last changed
- 2024-01-07 11:09:23
@article{6b7bd893-dece-465e-8e35-f82be786355e, abstract = {{The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard deviation, CONGA, J-INDEX, and MAGE. We found that vildagliptin improved the glycemic condition compared to placebo: mean glycemic levels, and both GRADE and M-VALUE, were reduced by vildagliptin (P < 0.01). Indices also showed that vildagliptin reduced glycemia without increasing the risk for hypoglycemia. Almost all indices of glycemic variability showed an improvement of the glycemic condition with vildagliptin (P < 0.02), though more marked differences were shown by the more complex indices. In conclusion, the study shows that four-sample preprandial glucose self-monitoring is sufficient to yield information on the vildagliptin effects on glycemic control and variability.}}, author = {{Tura, Andrea and Farngren, Johan and Schweizer, Anja and Foley, James E and Pacini, Giovanni and Ahrén, Bo}}, issn = {{1687-8337}}, language = {{eng}}, publisher = {{Hindawi Limited}}, series = {{International Journal of Endocrinology}}, title = {{Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.}}, url = {{http://dx.doi.org/10.1155/2015/484231}}, doi = {{10.1155/2015/484231}}, volume = {{2015}}, year = {{2015}}, }